Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study
Uložené v:
| Názov: | Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study |
|---|---|
| Autori: | Lars Tönges, David Mengel, Carmen Richinger, Anna Lipinski, Monika Balzer-Geldsetzer, Sabrina Kretschmer, Stefan Lorenzl, Christian Schmotz, Christopher Kruse, Richard Dodel, Stephan Klebe, Malte Verheyen, Dirk Woitalla, Anette Schrag |
| Zdroj: | Pharmacoeconomics |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2021. |
| Rok vydania: | 2021 |
| Predmety: | Medizin, Quality of Life Research, Europe [MeSH], Cost of Illness [MeSH], Hospitalization [MeSH], Humans [MeSH], Pharmacoeconomics and Health Outcomes, Parkinson Disease/therapy [MeSH], Public Health, France [MeSH], Health Economics, Germany [MeSH], Health Administration, Original Research Article, Health Care Costs [MeSH], Parkinson Disease, Health Care Costs, 3. Good health, Europe, Hospitalization, 03 medical and health sciences, 0302 clinical medicine, Cost of Illness, Germany, Humans, France |
| Popis: | The Care of Late-Stage Parkinsonism (CLaSP) study aimed to collect qualitative and standardized patient data in six European countries (France, Germany, Netherlands, Portugal, UK, Sweden) to enable a detailed evaluation of the underexplored late stages of the disease (Hoehn and Yahr stage > 3) using clinical, neuropsychological, behavioral, and health economic data. The aim of this substudy was to provide a health economic evaluation for the German healthcare system.In Germany, 228 patients were included in the study. Costs were calculated from a societal perspective for a 3-month period. Univariate analyses were performed to identify cost-driving predictors. Total and direct costs were analyzed using a generalized linear model with a γ-distributed dependent variable and log link function. Indirect costs were analyzed using a binomial generalized linear model with probit link function.The mean costs for the 3-month period were approximately €20,000. Informal care costs and hospitalization are approximately €11,000 and €5000. Direct costs amounted to 89% of the total costs, and the share of indirect costs was 11%. Independent predictors of total costs were the duration of the disease and age. The duration of the disease was the main independent predictor of direct costs, whereas age was an independent predictor of indirect costs.Costs in the late stage of the disease are considerably higher than those found in earlier stages. Compared to the latter, the mean number of days in hospital and the need for care is increasing. Informal caregivers provide most of the care.The protocol was registered at ClinicalTrials.gov as NCT02333175 on 7 January, 2015. |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1179-2027 1170-7690 |
| DOI: | 10.1007/s40273-021-01011-y |
| Prístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s40273-021-01011-y.pdf https://pubmed.ncbi.nlm.nih.gov/33738776 https://link.springer.com/article/10.1007/s40273-021-01011-y https://www.ncbi.nlm.nih.gov/pubmed/33738776 https://ideas.repec.org/a/spr/pharme/v39y2021i5d10.1007_s40273-021-01011-y.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079299 https://europepmc.org/articles/PMC8079299/ https://link.springer.com/content/pdf/10.1007/s40273-021-01011-y.pdf https://repository.publisso.de/resource/frl:6464975 https://discovery-pp.ucl.ac.uk/id/eprint/10128662/ |
| Rights: | CC BY NC URL: http://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) . |
| Prístupové číslo: | edsair.doi.dedup.....b21c0ffb10dd76e6abc2c58e816ed12c |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | The Care of Late-Stage Parkinsonism (CLaSP) study aimed to collect qualitative and standardized patient data in six European countries (France, Germany, Netherlands, Portugal, UK, Sweden) to enable a detailed evaluation of the underexplored late stages of the disease (Hoehn and Yahr stage > 3) using clinical, neuropsychological, behavioral, and health economic data. The aim of this substudy was to provide a health economic evaluation for the German healthcare system.In Germany, 228 patients were included in the study. Costs were calculated from a societal perspective for a 3-month period. Univariate analyses were performed to identify cost-driving predictors. Total and direct costs were analyzed using a generalized linear model with a γ-distributed dependent variable and log link function. Indirect costs were analyzed using a binomial generalized linear model with probit link function.The mean costs for the 3-month period were approximately €20,000. Informal care costs and hospitalization are approximately €11,000 and €5000. Direct costs amounted to 89% of the total costs, and the share of indirect costs was 11%. Independent predictors of total costs were the duration of the disease and age. The duration of the disease was the main independent predictor of direct costs, whereas age was an independent predictor of indirect costs.Costs in the late stage of the disease are considerably higher than those found in earlier stages. Compared to the latter, the mean number of days in hospital and the need for care is increasing. Informal caregivers provide most of the care.The protocol was registered at ClinicalTrials.gov as NCT02333175 on 7 January, 2015. |
|---|---|
| ISSN: | 11792027 11707690 |
| DOI: | 10.1007/s40273-021-01011-y |